Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3.72 USD 1.09% Market Closed
Market Cap: 572.3m USD
Have any thoughts about
Mereo Biopharma Group PLC?
Write Note

P/FCFE
Price to FCFE

-21.2
Current
-11.7
Median
25.2
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-21.2
=
Market Cap
572.3m USD
/
FCFE
-21.5m GBP
All Countries
Close
Market Cap P/FCFE
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
572.3m USD -21.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 227 395.3
US
Abbvie Inc
NYSE:ABBV
312.7B USD 12.5
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 26.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD -87.8
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 11.2
US
Epizyme Inc
F:EPE
94.1B EUR -425.2
AU
CSL Ltd
ASX:CSL
133.6B AUD 79
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 24.5
US
Seagen Inc
F:SGT
39.3B EUR -58.5
NL
argenx SE
XBRU:ARGX
34.8B EUR -109.8
 
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
Average P/FCFE: 30.8
Negative Multiple: -21.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 227 395.3
US
Abbvie Inc
NYSE:ABBV
12.5
US
Amgen Inc
NASDAQ:AMGN
26.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -87.8
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -425.2
AU
CSL Ltd
ASX:CSL
79
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More